Inhibition of Chk1 stimulates cytotoxic action of
platinum-based drugs and TRAIL combination in human prostate
cancer cells

J 2024

Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells

KRKOŠKA, Martin; Kamil PARUCH; Tereza ŠOŠOLÍKOVÁ; Gerardo VÁZQUEZ-GÓMEZ; Jarmila HERŮDKOVÁ et al.

Základní údaje

Originální název

Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells

Autoři

KRKOŠKA, Martin; Kamil PARUCH; Tereza ŠOŠOLÍKOVÁ; Gerardo VÁZQUEZ-GÓMEZ; Jarmila HERŮDKOVÁ; Jan NOVOTNÝ; Petra OVESNÁ ; Petr SOVA a Alena HYRŠLOVÁ VACULOVÁ

Vydání

Biological Chemistry, Walter de Gruyter GmbH, 2024, 1431-6730

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.400

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/24:00136147

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

checkpoint kinase 1; SCH900776; cisplatin; TRAIL; cell death; prostate cancer

Štítky

14313010, 14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 2. 2025 18:40, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Checkpoint kinase 1 (Chk1) plays an important role in regulation of the cell cycle, DNA damage response and cell death, and represents an attractive target in anticancer therapy. Small-molecule inhibitors of Chk1 have been intensively investigated either as single agents or in combination with various chemotherapeutic drugs and they can enhance the chemosensitivity of numerous tumor types. Here we newly demonstrate that pharmacological inhibition of Chk1 using potent and selective inhibitor SCH900776, currently profiled in phase II clinical trials, significantly enhances cytotoxic effects of the combination of platinum-based drugs (cisplatin or LA-12) and TRAIL (tumor necrosis factor-related apoptosis inducing ligand) in human prostate cancer cells. The specific role of Chk1 in the drug combination-induced cytotoxicity was confirmed by siRNA-mediated silencing of this kinase. Using RNAi-based methods we also showed the importance of Bak-dependent mitochondrial apoptotic pathway in the combined anticancer action of SCH900776, cisplatin and TRAIL. The triple drug combination-induced cytotoxicity was partially enhanced by siRNA-mediated Mcl-1 silencing. Our findings suggest that targeting Chk1 may be used as an efficient strategy for sensitization of prostate cancer cells to killing action of platinum-based chemotherapeutic drugs and TRAIL.

Návaznosti

EF16_025/0007381, projekt VaV

Název: Preklinická progrese nových organických sloučenin s cílenou biologickou aktivitou

LM2023052, projekt VaV

Název: Národní infrastruktura chemické biologie

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní infrastruktura chemické biologie

Citovat

KRKOŠKA, Martin; Kamil PARUCH; Tereza ŠOŠOLÍKOVÁ; Gerardo VÁZQUEZ-GÓMEZ; Jarmila HERŮDKOVÁ; Jan NOVOTNÝ; Petra OVESNÁ; Petr SOVA a Alena HYRŠLOVÁ VACULOVÁ. Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells. Biological Chemistry. Walter de Gruyter GmbH, 2024, roč. 405, č. 6, s. 395-406. ISSN 1431-6730. Dostupné z: https://doi.org/10.1515/hsz-2023-0111.

@article{2408345,
   author = {Krkoška, Martin and Paruch, Kamil and Šošolíková, Tereza and VázquezandGómez, Gerardo and Herůdková, Jarmila and Novotný, Jan and Ovesná, Petra and Sova, Petr and Hyršlová Vaculová, Alena},
   article_number = {6},
   doi = {https://doi.org/10.1515/hsz-2023-0111},
   keywords = {checkpoint kinase 1; SCH900776; cisplatin; TRAIL; cell death; prostate cancer},
   language = {eng},
   issn = {1431-6730},
   journal = {Biological Chemistry},
   title = {Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells},
   url = {https://www.degruyter.com/document/doi/10.1515/hsz-2023-0111/html},
   volume = {405},
   year = {2024}
}

TY  - JOUR
ID  - 2408345
AU  - Krkoška, Martin - Paruch, Kamil - Šošolíková, Tereza - Vázquez-Gómez, Gerardo - Herůdková, Jarmila - Novotný, Jan - Ovesná, Petra - Sova, Petr - Hyršlová Vaculová, Alena
PY  - 2024
TI  - Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells
JF  - Biological Chemistry
VL  - 405
IS  - 6
SP  - 395-406
EP  - 395-406
PB  - Walter de Gruyter GmbH
SN  - 14316730
KW  - checkpoint kinase 1
KW  - SCH900776
KW  - cisplatin
KW  - TRAIL
KW  - cell death
KW  - prostate cancer
UR  - https://www.degruyter.com/document/doi/10.1515/hsz-2023-0111/html
N2  - Checkpoint kinase 1 (Chk1) plays an important role in regulation of the cell cycle, DNA damage response and cell death, and represents an attractive target in anticancer therapy. Small-molecule inhibitors of Chk1 have been intensively investigated either as single agents or in combination with various chemotherapeutic drugs and they can enhance the chemosensitivity of numerous tumor types. Here we newly demonstrate that pharmacological inhibition of Chk1 using potent and selective inhibitor SCH900776, currently profiled in phase II clinical trials, significantly enhances cytotoxic effects of the combination of platinum-based drugs (cisplatin or LA-12) and TRAIL (tumor necrosis factor-related apoptosis inducing ligand) in human prostate cancer cells. The specific role of Chk1 in the drug combination-induced cytotoxicity was confirmed by siRNA-mediated silencing of this kinase. Using RNAi-based methods we also showed the importance of Bak-dependent mitochondrial apoptotic pathway in the combined anticancer action of SCH900776, cisplatin and TRAIL. The triple drug combination-induced cytotoxicity was partially enhanced by siRNA-mediated Mcl-1 silencing. Our findings suggest that targeting Chk1 may be used as an efficient strategy for sensitization of prostate cancer cells to killing action of platinum-based chemotherapeutic drugs and TRAIL.
ER  -

KRKOŠKA, Martin; Kamil PARUCH; Tereza ŠOŠOLÍKOVÁ; Gerardo VÁZQUEZ-GÓMEZ; Jarmila HERŮDKOVÁ; Jan NOVOTNÝ; Petra OVESNÁ; Petr SOVA a Alena HYRŠLOVÁ VACULOVÁ. Inhibition of Chk1 stimulates cytotoxic action of platinum-based drugs and TRAIL combination in human prostate cancer cells. \textit{Biological Chemistry}. Walter de Gruyter GmbH, 2024, roč.~405, č.~6, s.~395-406. ISSN~1431-6730. Dostupné z: https://doi.org/10.1515/hsz-2023-0111.

Přehled o publikaci